The FDA has tasked drug developers to try to treat neurodegenerative diseases such as Alzheimer's before symptoms start to appear. That approach is expected to enhance efficacy in a field that remains long-challenged. One of the hardest parts is finding those patients as early as possible to treat them in trials with promising clinical candidates.